Rockefeller Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$52.1K Buy
11,100
+9,000
+429% +$46.6K ﹤0.01% 3438
2026
Q2
$9.8K Buy
2,100
+500
+31% +$3.69K ﹤0.01% 4026
2026
Q1
$10.5K Buy
1,600
+1,100
+220% +$7.21K ﹤0.01% 3971
2025
Q4
$2.88K Hold
500
– – ﹤0.01% 4232
2025
Q3
$2.18K Buy
+500
New +$2.18K ﹤0.01% 4074

Other funds holding UNCY

Rockefeller Capital Management's UNCY Position: Q3 2026 in Review

Rockefeller Capital Management increased its Unicycive Therapeutics (UNCY) stake by 429% in Q3 2026, buying an estimated $46.6K and bringing the position to 11,100 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3438.

Rockefeller Capital Management first reported a position in UNCY in Q3 2025 and has held it in 5 quarters since. 91 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Rockefeller Capital Management held 11,100 shares of Unicycive Therapeutics worth $52.1K as of Q3 2026.
  • Rockefeller Capital Management bought 9,000 Unicycive Therapeutics shares in Q3 2026, an estimated $46.6K.
  • Unicycive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3438 holding.
  • Rockefeller Capital Management first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 91 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.